Status:

TERMINATED

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder

Lead Sponsor:

Sanofi

Conditions:

Anxiety Disorders

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of the study is to evaluate the efficacy and safety of SR58611A (350 mg BID) compared to placebo in the prevention of relapse of anxiety, in patients with Generalized Anxiety Disorder impr...

Eligibility Criteria

Inclusion

  • For entry into the open phase:
  • Patients suffering from generalized anxiety disorder, according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria and assessed with the Mini International Neuropsychiatric Interview (MINI) plus Generalized Anxiety Disorder (GAD) module.
  • With a total score on the 14-item Hamilton Anxiety Rating Scale (HAM-A) \> 20 at V1(D-4) and V2 (D-1).
  • For entry into the double-blind randomized phase:
  • Improved patients with HAM-A score \< 11 at V7 (W12).

Exclusion

  • Inpatients.
  • Patients with a diagnosis of Major Depressive Disorder (DSM IV-TR) within 6 months of screening.
  • Patients with a MADRS total score \> 18 at screening or baseline.
  • Patients at immediate risk for suicidal behaviour.
  • Patients with other current (within 6 months) anxiety disorder according to the MINI
  • Patients with a lifetime history according to the MINI of: Bipolar disorder, Psychotic disorder, Antisocial personality disorder.
  • Patients with a current history according to the MINI of: Anorexia nervosa or bulimia nervosa in the past 6 months, Alcohol or substance dependence or abuse in the past 12 months, except nicotine or caffeine dependence.
  • The investigator will evaluate whether there are other reasons why a patient may not participate.

Key Trial Info

Start Date :

November 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2007

Estimated Enrollment :

257 Patients enrolled

Trial Details

Trial ID

NCT00397098

Start Date

November 1 2006

End Date

September 1 2007

Last Update

March 12 2009

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Sanofi-Aventis Administrative Office

Macquarie Park, Australia

2

Sanofi-Aventis Administrative Office

Santiago, Chile

3

Sanofi-Aventis Administrative Office

Paris, France

4

Sanofi-Aventis Administrative Office

Berlin, Germany

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder | DecenTrialz